Artios collaborates with Novartis to create next generation DDR cancer therapies
LONDON: Arix Bioscience’s portfolio company Artios Pharma Limited announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’ Radioligand Therapies (RLT). Under the three-year collaboration, Artios and Novartis will perform target discovery…